Back to my company list

Biovista

The AI engine Fit Assessment

Beta

Biovista effectively leverages machine learning for drug repositioning, pattern discovery, and expanding therapeutic options, making it a strong fit for the specified requirements.

Blurb

Biovista is a pioneer of AI and systematic drug repositioning.

HQ Location

United States

Founded

1999

Employees

11 - 50

Total funding raised

Not available

Last Funding Event

Not available

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing

Developer of an artificial intelligence-based biotechnology platform intended to deliver custom drug repositioning, drug de-risking, and clinical hold services for the biopharma industry. The company's platform offers systematic discovery services based on proprietary technology and a unit that finds novel uses for drugs and profiles and their side effects using mechanism-of-action analytics, enabling medical professionals to find cures for oncology, auto-immune, and other rare diseases.